Short answer
McKesson Corporation (MCK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $111.0B (up 7.6% year over year) with net income of $1.2B.
Q3 2026 key financials · XBRL
- Revenue
- $111.0B
- +7.6% YoY · +5.3% QoQ
- Net income
- $1.2B
- +9.7% YoY · +98.4% QoQ
- Operating margin
- 1.4%
- Gross margin
- 3.6%
- EPS (diluted)
- $10.38
- +16.5% YoY · +101.6% QoQ
Source: XBRL data from the McKesson Corporation (MCK) Q3 2026 10-Q on SEC EDGAR. USD.
McKesson Corporation Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $110,957M, up 8% YoY from $103,150M, driven by pharmaceutical volumes and specialty pharmaceuticals
- Gross margin 3.57% vs 3.43% YoY, operating-expense ratio 2.12% vs 2.07%
- Best segment Oncology & Multispecialty: revenue $14,980M, up 24%; worst margin trend Medical-Surgical Solutions: 5.30% vs 7.47%
- Operating cash flow $2,850M vs $1,502M; cash balance $6,619M vs $4,068M at March 31
- Capital deployment: $3,400M repurchases and $198M dividends; regulatory uncertainty, drug pricing, and opioid liabilities remained headwinds
Risk Factors
- No material changes to 10-K risk factors during the quarter
- Carried-forward risks remain unchanged, including regulatory, legal, operational, competitive, market, liquidity, debt, currency and concentration exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other McKesson Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.